NCT05553678

Brief Summary

This study is a randomized, controlled, double-blinded, and parallel design study. A total 64 patients will be randomized to receive midazolam or normal saline during unruptured intracranial aneurysm clipping surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
64

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Sep 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 23, 2022

Completed
6 days until next milestone

Study Start

First participant enrolled

September 29, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

October 26, 2022

Status Verified

October 1, 2022

Enrollment Period

1 year

First QC Date

September 18, 2022

Last Update Submit

October 25, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Intraoperative movement

    Incidence

    During microscopic surgery

Secondary Outcomes (6)

  • Motor evoked potential amplitude

    immediately postoperative surgery

  • Motor evoked potential Latency

    immediately postoperative surgery

  • Duration of mechanical ventilation time

    End of surgery to extubation time

  • Duration of ICU stay

    From date of ICU admission until the date of first discharge from ICU, assessed up to 1 week

  • Satisfaction score for intraoperative environment

    immediately postoperative surgery

  • +1 more secondary outcomes

Study Arms (2)

treatment group

EXPERIMENTAL

Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.

Drug: Midazolam

Control group

PLACEBO COMPARATOR

Normal saline (0.03 ml/kg/30 min) will administered during UIA clipping through microscope.

Drug: Normal saline

Interventions

Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.

treatment group

Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.

Control group

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who undergo elective unruptured intracranial aneurysm clipping surgery
  • American Society of Anesthesiologists grade 1,2,3
  • age \> 18 year old

You may not qualify if:

  • Refuse to participate to the study
  • Body Mass Index \< 18.5 kg/m2 or \> 35 kg/m2
  • Allergic history of benzodiazepine
  • Pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea

RECRUITING

MeSH Terms

Interventions

MidazolamSaline Solution

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Chang-Hoon Koo

    Seoul National University Bundang Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chang-Hoon Koo

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

September 18, 2022

First Posted

September 23, 2022

Study Start

September 29, 2022

Primary Completion

September 30, 2023

Study Completion

December 31, 2023

Last Updated

October 26, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations